AHB(SH:688639) Sou Hu Cai Jing·2025-08-02 06:58Group 1 - The core point of the article is that Huaheng Biological (688639.SH) is planning to issue overseas shares (H-shares) and list on the Hong Kong Stock Exchange to enhance its global development strategy and brand influence [1] - The company aims to optimize its capital structure, broaden financing channels, and improve governance and overall strength through this H-share listing [1] - The specific details of the H-share listing are still under discussion with relevant intermediaries, and it will not lead to changes in the controlling shareholder or actual controller of the company [1] Group 2 - Huaheng Biological was listed on the A-share market in 2021 and focuses on synthetic biology technology, primarily engaged in the R&D, production, and sales of bio-based products [3] - The company's main products include amino acids, vitamins, bio-based new material monomers, and other products, which are widely used in various fields such as intermediates, animal nutrition, personal care, functional foods, and plant nutrition [3] - The company has established a sustainable innovation capability through its Hefei Research Institute and has high-quality delivery capabilities across four production bases located in Changfeng, Qinhuangdao, Bayannaoer, and Chifeng [3]